Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456885 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL19612305 | 0.92 | ALDH1A1 (0.47) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL10989791 | 0.86 | ALDH1A1 (0.54) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL22960674 | 0.85 | TSHR (0.43) | KDM4EALDH1A1MAPTL3MBTL1TDP1 | |
| SCHEMBL10993897 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL490194 | 0.84 | MAPT (0.52) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL16569803 | 0.81 | ALDH1A1 (0.42) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL31544285 | 0.81 | TSHR (0.43) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL5030843 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL20016206 | 0.80 | ESR1 (0.43) | KDM4EALDH1A1RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 834 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382868-B2 | Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same | ICURE PHARMACEUTICAL INC. (KR) | 2022-07-12 | — | — | US | claimed |
| CN-107652222-B | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2021-09-10 | — | — | CN | claimed |
| US-10919909-B2 | Photoinitiated reactions | LINTFIELD LIMITED (GB) | 2021-02-16 | — | — | US | claimed |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | LINTFIELD LIMITED (GB) | 2019-07-11 | — | — | US | claimed |
| US-20190046463-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | ICURE PHARMACEUTICAL INC. (KR) | 2019-02-14 | — | — | US | claimed |
| EP-3415141-A1 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME | Icure Pharmaceutical Inc. (KR) | 2018-12-19 | — | — | EP | claimed |
| CN-108697657-A | Ultraviolet-curable hydrogel resin for transdermal administration, hydrogel, and poultice containing same | Icure药品株式会社 | 2018-10-23 | — | — | CN | claimed |
| CN-101802022-B | Photoinitiators for energy curing | LAMBERTI SPA | 2013-03-27 | — | — | CN | claimed |
| EP-2190887-B1 | PHOTOINITIATORS FOR ENERGY CURING | LAMBERTI SPA (IT) | 2011-05-04 | — | — | EP | claimed |
| CN-101802022-A | Photoinitiators for energy curing | LAMBERTI SPA | 2010-08-11 | — | — | CN | claimed |
| US-20100196826-A1 | Photoinitiators for Energy Curing | LAMBERTI SPA (IT) | 2010-08-05 | — | — | US | claimed |
| EP-2190887-A1 | PHOTOINITIATORS FOR ENERGY CURING | Lamberti Spa (IT) | 2010-06-02 | — | — | EP | claimed |
| US-20100093883-A1 | Hydroxamic Esters as Photoinitiators | LAMBERTI SPA (IT) | 2010-04-15 | — | — | US | claimed |
| CN-101646564-A | Hydroxamates as photoinitiators | LAMBERTI SPA IT | 2010-02-10 | — | — | CN | claimed |
| EP-2121323-A1 | HYDROXAMIC ESTERS AS PHOTOINITIATORS | Lamberti Spa (IT) | 2009-11-25 | — | — | EP | claimed |
| WO-2009037130-A1 | PHOTOINITIATORS FOR ENERGY CURING | LAMBERTI SPA (IT) | 2009-03-26 | — | — | WO | claimed |
| WO-2008104436-A1 | HYDROXAMIC ESTERS AS PHOTOINITIATORS | LAMBERTI SPA (IT) | 2008-09-04 | — | — | WO | claimed |
| EP-0138754-A2 | Photocurable compositions | CIBA-GEIGY AG (CH) | 1985-04-24 | — | — | EP | claimed |
| US-12637600-B2 | Photocurable composition, cured product of same, photofusible resin composition and adhesive set | RESONAC CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| US-4506083-A | INITIATORS FOR PHOTOPOLYMERIZATION OR PHOTOCHEMICAL CROSSLINKING | CIBA-GEIGY CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637600-B2 | Photocurable composition, cured product of same, photofusible resin composition and adhesive set | ESD, CDH1, ASH2L | KDM4E 2247/4885ALDH1A1 95/4885RAB9A 4022/4885 |
| US-10919909-B2 | Photoinitiated reactions | KMO, DECR1, PPOX | KDM4E 2292/4885ALDH1A1 262/4885RAB9A 3269/4885 |
| US-20100196826-A1 | Photoinitiators for Energy Curing | PPOX, ECPAS, PTGES | KDM4E 1954/4885ALDH1A1 434/4885RAB9A 3210/4885 |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | DOHH, PAH, DBH | KDM4E 1292/4885ALDH1A1 179/4885RAB9A 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.